文献速递外周动脉疾病

当代股腘动脉腔内治疗外周动脉疾病后急性血栓性闭塞发生率及其预测因素

Incidence of Acute Thrombotic Occlusion and Its Predictors After Contemporary Femoropopliteal Endovascular Therapy in Patients With Peripheral Artery Disease.
PubMed 文献 · J Endovasc Ther · 2022-09-01

回顾性分析644例患者763条肢体接受当代股腘动脉腔内治疗,24个月急性血栓性闭塞发生率为4.3%±0.8%,药物涂层球囊组1.0%±0.7% vs 支架组5.8%±1.1%(p<0.01)。支架组中血液透析(HR 2.63)和累及腘动脉病变(HR 8.22)与急性血栓性闭塞风险独立相关。急性血栓性闭塞伴肌酸磷酸激酶升高与死亡或大截肢复合结局相关(HR 9.87)。

要点

  • 当代股腘动脉腔内治疗后24个月急性血栓性闭塞发生率为4.3%±0.8%,支架组高于药物涂层球囊组。
  • 支架组中血液透析(HR 2.63)和累及腘动脉病变(HR 8.22)与急性血栓性闭塞风险独立相关。
  • 急性血栓性闭塞伴肌酸磷酸激酶升高与死亡或大截肢复合结局相关(HR 9.87)。

核心结论

  • 当代股腘动脉腔内治疗后急性血栓性闭塞发生率较高,尤其使用支架时。
  • 血液透析和累及腘动脉病变与支架治疗患者急性血栓性闭塞风险显著相关。
  • 急性血栓性闭塞尤其伴肌酸磷酸激酶升高与后续死亡或大截肢复合结局风险增加相关。
  • 作者认为,无上述急性血栓性闭塞危险因素的患者可安全使用支架,但危险因素较多的患者应考虑非支架策略。

研究设计与样本

  • 回顾性研究,纳入2012年6月至2020年7月成功接受当代股腘动脉腔内治疗的644例患者763条肢体(慢性肢体威胁性缺血44%,累及腘动脉病变44%)。
  • 平均年龄75±9岁,男性71%,血液透析34%。
  • 使用器械:药物涂层支架220条、覆膜支架158条、药物洗脱支架150条、药物涂层球囊235条。
  • 采用Cox比例风险回归模型识别支架治疗后急性血栓性闭塞的基线预测因素。
  • 采用含三分类时依协变量(无急性血栓性闭塞、急性血栓性闭塞不伴肌酸磷酸激酶升高、急性血栓性闭塞伴肌酸磷酸激酶升高)的Cox模型评估对死亡或大截肢复合结局的影响。

主要发现

  • 总体人群24个月急性血栓性闭塞发生率为4.3%±0.8%。
  • 药物涂层球囊组24个月急性血栓性闭塞发生率为1.0%±0.7%,支架组为5.8%±1.1%(p<0.01)。
  • 支架治疗患者中,血液透析与急性血栓性闭塞风险独立相关(HR 2.63,p=0.02)。
  • 支架治疗患者中,累及腘动脉病变与急性血栓性闭塞风险独立相关(HR 8.22,p<0.01)。
  • 与无急性血栓性闭塞相比,急性血栓性闭塞不伴肌酸磷酸激酶升高与死亡或大截肢复合结局相关(HR 2.39,p=0.02),急性血栓性闭塞伴肌酸磷酸激酶升高亦相关(HR 9.87,p<0.01)。

关键数值与推荐

  • 急性血栓性闭塞定义为治疗段内急性发作的跛行和/或慢性肢体威胁性缺血体征,合并血管造影证实的闭塞性血栓形成。

临床怎么用

  • 作者认为,无血液透析和累及腘动脉病变的患者可安全使用支架。
  • 作者建议,具有上述危险因素的患者应考虑非支架策略。
  • 急性血栓性闭塞尤其伴肌酸磷酸激酶升高时死亡或截肢风险高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study investigated the incidence of acute thrombotic occlusion (ATO) and its predictors after contemporary femoropopliteal (FP) endovascular therapy (EVT) for peripheral artery disease. MATERIALS AND METHODS: We retrospectively examined 763 limbs (chronic limb-threatening ischemia [CLTI]: 44%, involving popliteal lesion: 44%) in 644 patients (mean age: 75±9 years, male: 71%, hemodialysis: 34%) who successfully underwent EVT with contemporary FP devices (drug-coated stent: n=220, stent graft: n=158, drug-eluting stent: n=150, drug-coated balloon [DCB]: n=235) from June 2012 to July 2020. The outcome measure was ATO defined as acute onset of claudication and/or signs of CLTI in combination with angiographic evidence of occlusive thrombus formation within the treated segment. Cox proportional hazards regression models were used to identify baseline characteristics associated with the incidence of ATO after EVT treated with scaffold. To determine the impact of ATO occurrence and creatine phosphokinase (CPK) elevation on the subsequent composite outcome of mortality or major amputation, we developed the Cox model in which the trichotomous variable (free from ATO, ATO without CPK elevation, and ATO with CPK elevation) was a time-dependent covariate. RESULTS: The 24-month incidence of ATO in the overall population was 4.3%±0.8% (DCB: 1.0%±0.7% vs scaffold: 5.8%±1.1%, p<0.01). Hemodialysis (hazard ratio [HR]: 2.63, p=0.02) and involving popliteal lesion (HR: 8.22, p<0.01) were independently associated with an increased risk of ATO in patients treated with scaffold. Both ATO without CPK elevation and ATO with CPK elevation were significantly associated with a composite outcome of mortality or major amputation comparing free from ATO, with an HR of 2.39 and 9.87, respectively (p=0.02 and p<0.01). CONCLUSION: We found a substantial incidence of ATO after contemporary FP-EVT, particularly with scaffold. Hemodialysis and involving popliteal lesion were significantly associated with ATO risk in patients treated with scaffold. The occurrence of ATO, particularly with CPK elevation, was associated with an increased risk of a subsequent composite outcome of mortality or major amputation. The scaffold was safely used in patients without those risk factors of ATO, but a non-scaffolding strategy should be considered for patients with more risk factors. CLINICAL IMPACT: The scaffold was safely used in patients without hemodialysis and involving popliteal lesion, but a non-scaffolding strategy should be considered for patients with those risk factors. The occurrence of ATO, particulary with CPK elevation, was of high risk of mortality or amputation.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Nakao S, Iida O, Takahara M, et al. Incidence of Acute Thrombotic Occlusion and Its Predictors After Contemporary Femoropopliteal Endovascular Therapy in Patients With Peripheral Artery Disease. J Endovasc Ther. 2022. PMID: 36052430. doi:10.1177/15266028221120519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。